Mylan NV responded Thursday to backlash over price increases for its EpiPen emergency allergy treatment by promising to reduce the costs that some patients pay, though the drugmaker stopped short of saying it would roll back prices or limit future increases.
EpiPen is a lifesaving treatment for millions whose allergies can send them into severe shock, including many schoolchildren who are advised to keep an injector handy at all times. A pack of two lists for $608.61, up 548% since Mylan began selling the drug in late 2007, according to Truven Health Analytics.
After widespread criticism recently, Mylan said Thursday that it was “doubling eligibility” for its EpiPen patient assistance program to 400% of the poverty level, saying that a family of four making $97,200 would now pay nothing out of pocket for a prescription.
t also said it would expand its savings card that currently covers copays by up to $100, which would put its maximum at $300. That means patients with commercial insurance could have their out-of-pocket expenses reduced. According to Mylan’s website, the current savings card cannot be used by those who are uninsured or who use government-funded insurance such as Medicare or Medicaid.
I did not read the whole thing but the patent that is challenged is for dosed above 30mg. Presumably this does not affect ATRS since they have an agreement regarding no litigation between them and MEDAC.
Apparently that particular patent is valid until 2029, question is does it matter? Where are such dosages used?
Claim 1 recites a method for treating inflammatory autoimmune diseases via subcutaneous administration of a pharmaceutically acceptable solvent containing methotrexate at a concentration of more than 30 mg/ml. Ex. 1001. The remaining twenty-one dependent claims:
cover various concentrations of methotrexate up to 100 mg/ml;
specify solvents that constitute the “pharmaceutically acceptable solvent”;
specify that the “inflammatory autoimmune diseases” are RA,juvenile arthritides, psoriasis, and several other
inflammatory autoimmune diseases; cover various dosage amounts; and
cover various self-administration devices, including a ready-made syringe and pen injection device, as well as storage containers (suchas a vial or carpule) for containing the medicament.
I'm on build 47.0.1 of Firefox(it's the last one that supports a side loaded coolpreview)and andre's suggestion (finance.yahoo.com/mb/atrs/?bypass=true) works perfect so farm, my old bookmark occasionally.
That worked a treat, I had just hit reload in the browser and lost the page(duhh forgot my own post)and got yours on the phone. Straight in no problem......for now.
The good solution here is to introduce an alternative with a lower price that users can switch to.
Lowering the price on EPI will not help us. Getting FDA to act would.
I'm having a hard time getting to this page, most of the time I just end up with a Blank page when I click on the saved bookmark(for some reason I never have this problem on the phone). Anyhow a lot of times when I hit reload on the page it will come up blank again.
I have found that to toggle between Topics and Messages will update without loosing the page.
Maybe it's only me who has this problem but if not I hope it works for you guys also. I've got this problem regardless of what beowser I use on the PC.
The injector in question has already been approved TWICE. So how can you be so sure it's the injector?
Why would you buy 6000 shares at 1.50'ish when 100 would be enough if you want to send a message?
19:59 $ 1.38 50
19:30 $ 1.50 High 300
19:30 $ 1.50 High 700
19:30 $ 1.49 300
19:12 $ 1.49 100
19:12 $ 1.49 4,000
19:12 $ 1.49 900
19:04 $ 1.49 100
18:33 $ 1.35 Low 400
It's from the end paragraph of a rather long joke(or not) that starts like this:
A Japanese company (Toyota) and an American company (General Motors) decided to have a canoe race on the Missouri River . Both teams practiced long and hard to reach their peak performance before the race.
On the big day, the Japanese won by a mile .
The Americans, very discouraged and depressed, decided to investigate the reason for the crushing defeat. A management team made up of senior management was formed to investigate and recommend appropriate action.
Their conclusion was the Japanese had 8 people paddling and 1 person steering, while the American team had 7 people steering and 2 people paddling.
Feeling a deeper study was in order, American management hired a consulting company and paid them a large amount of money for a second opinion.
GM has spent the last thirty years moving all its factories out of the US, claiming they can't make money paying American wages.
TOYOTA has spent the last thirty years building more than a dozen plants inside the US. The last quarter's results:
TOYOTA makes 4 billion in profits while GM rack s up 9 billion in losses.
GM folks are still scratching their heads, and collecting bonuses...
Well see Vadar, If you are still here pumping in October I'll come around, time to go for lunch here......
So your research here was not exactly pristine was it?
stockvadar • Jul 14, 2016 7:16 PM
We have every confidence that foremost that Cel-Sci is/has been working with the FDA over required patients. If more are required, we won't lose sleep knowing the study is on the home stretch anyway. No doubt Cel-Sci will pursue the best path possible. Our money rests on Multikine knowing through great DD, it appears to have exceptional properties.
These are exciting times. -sv (48 cents/share seems to be a once-lifetime bargain) Less
"We see Antares on the start of what will be over 1-2 a mega run."
Lets see, in may you saw them heading for de-listing......so what will the flavor be in end September?
You are welcome. Your BS is quite entertaining and varying from day to day and week to week. Your research seem somewhat shallow and the consortium somewhat hollow. So how did Cel_Sci work out for you in the end?